Shanghai, China—Oct. 28th, 2019. OnQuality Pharmaceuticals Ltd., a start-up pharmaceutical company focusing on mitigating on-target toxicities for cancer patients who are using multi-tyrosine kinase inhibitors as their cancer therapies, today announced a $15 million series A venture capital financing.
